SPOTLIGHT: FDA warns J&J unit on heart drug marketing


Promotional pens and mouse pads landed a Johnson & Johnson unit it hot water with the FDA. The tchotchkes, which featured the heart drug Natrecor, didn't include warnings about its "numerous risks," the agency said. Report

Suggested Articles

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.